- What is an opioid-sparing protocol?
- How common is chronic use after spine surgery?
- What predicts prolonged use?
- What strategies replace opioids?
- Clinical consensus and practical application
01 What is an opioid-sparing protocol?
An opioid-sparing protocol is a perioperative pain management plan built around the deliberate goal of minimizing opioid exposure — before, during, and after spine surgery — by combining several non-opioid mechanisms instead of relying on a single class of drug. It is not the absence of opioids; it is a plan that uses them as one tool among several, at the lowest effective dose, for the shortest necessary time.
The motivation is not abstract. The United States has faced a documented opioid overdose epidemic for two decades (Murthy, 2016; Rudd et al., 2016; Kolodny et al., 2015; King et al., 2014), and surgery is a well-established entry point into long-term opioid use: a meaningful share of opioid-naive patients who receive an opioid prescription after surgery go on to use opioids chronically months later (Sun et al., 2016a; Brummett et al., 2017; Clarke et al., 2014). Spine surgery specifically carries some of the highest rates of preoperative opioid use and postoperative persistent use among all surgical specialties (Dunn et al., 2018a; Schoenfeld et al., 2017; Walid et al., 2007).
Being opioid-sparing does not mean avoiding pain control — it means controlling pain through several mechanisms at once, so no single drug (and its risks) has to do all the work.
The exact incidence depends on the definition and the population studied, but converging estimates are consistent. In one cross-sectional study specifically in major spine surgery, a substantial proportion of previously opioid-naive patients were still filling opioid prescriptions well beyond the expected surgical recovery window (Dunn et al., 2018a). Broader surgical cohorts confirm the same pattern: opioid-naive patients undergoing common procedures have a measurable, non-trivial risk of becoming new chronic users (Sun et al., 2016a; Brummett et al., 2017), and this risk extends even to procedures classified as low-risk, where prolonged use is not explained by expected postoperative pain alone (Alam et al., 2012; Wunsch et al., 2016). Orthopedic joint replacement literature — a useful comparator field with more mature data — shows persistent postoperative opioid use in a meaningful subset of patients, tracked out to one and five years (Sun et al., 2017; Singh & Lewallen, 2010; Farag et al., 2013).
- Preoperative opioid use — by far the strongest single predictor of postoperative persistent use. (Armaghani et al., 2013; Armaghani et al., 2014; Lee et al., 2014)
- Depression and anxiety, including pain catastrophizing, independently predict both opioid consumption and misuse. (Armaghani et al., 2013; Dunn et al., 2018b; Arteta et al., 2016)
- Greater surgical intensity — more levels fused, longer procedures — correlates with higher risk of prolonged use. (Schoenfeld et al., 2017; Anderson et al., 2015; Connolly et al., 2017)
- Workers’ compensation status and active litigation are consistently associated with worse pain outcomes and higher opioid use. (Anderson et al., 2015; Lawrence et al., 2008)
- A large initial prescription — more days’ supply than needed — independently raises the odds of long-term use, regardless of the procedure. (Shah et al., 2017; Bartels et al., 2016)
Multimodal analgesia means combining drugs and techniques that act on different pain pathways at the same time, so their effects add up while their individual side effects (including opioid-related ones) do not. In spine surgery, the combinations with the most direct evidence include perioperative intravenous lidocaine, low-dose ketamine, and dexmedetomidine, layered onto standard multimodal building blocks such as scheduled acetaminophen and NSAIDs where not contraindicated (Devin et al., 2014; Devin & McGirt, 2015; Gan et al., 2018). A comprehensive multimodal protocol applied across multilevel spine surgery has been shown to reduce total opioid consumption compared with a standard opioid-centered approach (Mathiesen et al., 2013).
| Agent | Evidence in spine surgery |
|---|---|
| Lidocaine (IV infusion) | Reduces pain scores and opioid consumption when infused intraoperatively and into early recovery in complex spine surgery (Farag et al., 2013; Kim et al., 2014) |
| Ketamine (low dose) | Reduces perioperative opioid consumption in opioid-dependent spine surgery patients; meta-analysis confirms an opioid-sparing effect across randomized trials (Loftus et al., 2010; Pendi et al., 2017) |
| Dexmedetomidine | Comparable postoperative analgesia to low-dose ketamine infusion in spine surgery, as an alternative or complementary agent (Garg et al., 2016) |
One important caution: intraoperative ketamine has also been studied for postoperative delirium prevention in older adults undergoing major surgery, with a large randomized trial finding no benefit for that specific outcome and a signal of harm at higher doses — a reminder that opioid-sparing agents are not risk-free and dosing matters. (Avidan et al., 2017)
This is not a fringe position. The CDC issued formal prescribing guidelines for chronic pain specifically to curb overprescription while preserving pain control (Dowell et al., 2016), and in 2019 a multidisciplinary working group under the American Society for Enhanced Recovery and the Perioperative Quality Initiative published a joint consensus statement defining persistent postoperative opioid use, summarizing its incidence and risk factors, and recommending health-system-level changes to reduce it (Hooten et al., 2017). Enhanced recovery frameworks more broadly have made opioid-sparing multimodal analgesia a core pillar, not an optional add-on (Kent et al., 2019).
One useful way to understand unintended prolonged opioid use is as the result of overlapping factors — physiological, psychological, and prescribing-related — rather than a single cause, which is exactly why a single-mechanism solution (more opioids, or simply fewer) rarely works on its own. (Bicket et al., 2017)
Overprescription is a separate but related problem from chronic use: patients are often sent home with more opioid tablets than they end up using. A systematic review found that a substantial share of prescribed opioid tablets after surgery go unused (Hill et al., 2017), and prescribing patterns for common general surgical procedures show wide, unexplained variation in dose and duration between surgeons and institutions (Bartels et al., 2016). Leftover pills are not a neutral outcome: they are commonly stored insecurely at home, creating a documented pathway for diversion and misuse by someone other than the patient (Nguyen et al., 2011), and a larger initial prescription is itself an independent predictor of long-term use (Shah et al., 2017).
Spine surgery has a specific complication: it treats pain as its primary outcome, and a meaningful share of patients arrive already on chronic opioids before surgery is even considered (Armaghani et al., 2013; Schoenfeld et al., 2017; Walid et al., 2007). That baseline exposure changes everything about perioperative planning — it predicts higher perioperative opioid requirements, worse self-reported outcomes, and a lower probability of achieving opioid independence after surgery, independent of how technically successful the operation was (Armaghani et al., 2014; Lee et al., 2014). Long-term outcome studies in lumbar fusion and cervical arthrodesis populations consistently find that preoperative opioid use and workers’ compensation status track with worse functional results years later (Lawrence et al., 2008; Mirza et al., 2013; Brat et al., 2018), and postoperative persistent use itself is associated with excess health care resource utilization (Brat et al., 2018).
In practice, this points toward a structured approach: identify preoperative opioid use and psychosocial risk factors before surgery, set realistic expectations about post-surgical pain trajectory, build a multimodal plan from the start rather than adding it after opioids fail, and prescribe the discharge supply based on expected need for that specific procedure rather than a fixed default (Hah et al., 2017; Devin & McGirt, 2015). A structured comparative treatment approach (fusion vs. conservative treatment, discogenic pain management) also affects the opioid trajectory independent of the analgesic protocol itself (Mino et al., 2017).
None of this eliminates opioids from spine surgery — for many patients they remain part of an appropriate short-term plan. The goal is to stop treating them as the default first and only option.
The specific drugs vary by institution and by phase of care (intraoperative vs. discharge prescription), but a small group of opioids accounts for most perioperative use in spine surgery, as reflected across the clinical literature reviewed here (Hah et al., 2017; Kent et al., 2019):
- Fentanyl. Short-acting, fast-onset opioid used almost universally during surgery itself, often as part of the anesthetic technique rather than for post-discharge pain.
- Morphine. A standard reference opioid for moderate-to-severe postoperative pain, used intravenously in the hospital and sometimes as an oral formulation afterward.
- Hydromorphone (Dilaudid). A more potent alternative to morphine, commonly used intravenously for acute inpatient pain after major spine surgery.
- Oxycodone. One of the most frequently prescribed oral opioids for the discharge period, often combined with acetaminophen.
- Hydrocodone. A commonly prescribed oral opioid for outpatient recovery, typically formulated together with acetaminophen.
- Tramadol. A weaker opioid with additional non-opioid mechanisms, sometimes used as a step-down option later in recovery.
- Methadone. A long-acting opioid used intraoperatively in some enhanced-recovery spine protocols specifically for its additional NMDA-receptor antagonist activity, which may itself contribute to an opioid-sparing effect.
This list is for general orientation only — it is not guidance on dosing, combining, or self-administering any of these medications. Which opioid is used, if any, and at what dose, is a clinical decision made by the surgical and anesthesia team for each specific patient.
A final reflection
The evidence here is unusually consistent for a perioperative topic: preoperative opioid use is the strongest predictor of trouble after surgery (Armaghani et al., 2013; Armaghani et al., 2014; Lee et al., 2014), multimodal non-opioid strategies measurably reduce consumption when applied deliberately rather than as an afterthought (Farag et al., 2013; Loftus et al., 2010; Mathiesen et al., 2013), and the professional consensus has moved from "watch for this" to formal guidance on how to structure care around it (Dowell et al., 2016; Hooten et al., 2017).
What this means for a patient weighing spine surgery: ask directly whether the surgical team has a structured multimodal pain plan, whether your own preoperative opioid use (if any) will be assessed as part of surgical planning, and how the discharge prescription will be sized to your actual procedure rather than handed out by default. Those questions predict more about your postoperative pain trajectory than the surgical technique itself.